Arzerra (ofatumumab) is in a class of drugs called anti-CD20-directed monoclonal antibodies. It is used to treat chronic lymphocytic leukemia (CLL) in patients who have further disease after treatment with the anti-cancer drugs fludarabine and alemtuzumab.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
 

 

Related Information

• FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)

Regulatory History and Labeling from Drugs@FDA

• Arzerra (ofatumumab) Labeling Information